This post is from a suggested group
Progress in Combating Neglected Diseases: Key Trends in the Human Trypanosomiasis (Sleeping Sickness) Market
Description
The Human Trypanosomiasis (Sleeping Sickness) Market addresses a critical challenge in sub-Saharan Africa. Sleeping sickness is a Neglected Tropical Disease (NTD) caused by the Trypanosoma brucei parasite, transmitted by the tsetse fly. The disease progresses from an initial blood-stage infection to a late stage involving the central nervous system. Historically, treatment has been extremely challenging due to the high toxicity of older drugs, such as the arsenical melarsoprol, which was associated with significant fatality rates in treated patients.
The market has recently seen significant positive advancements, primarily driven by a renewed global focus on NTD eradication and the vital work of public-private partnerships like the Drugs for Neglected Diseases Initiative (DNDi). A major trend is the shift toward safer and more effective combination therapies. The Nifurtimox-Eflornithine Combination Therapy (NECT) has significantly improved treatment outcomes for the…